Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02951819
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT02928029
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸Pacific Oncology/Hematology Associates, Encinitas, California, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Pharmacyclics Switzerland GmbH
- Target Recruit Count
- 74
- Registration Number
- NCT02902965
- Locations
- 🇨🇿
Fakultní nemocnice Brno, Brno, Czechia
🇨🇿Fakultní nemocnice Hradec Králové, Nový Hradec Králové, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czechia
Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT02893111
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT02877082
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 224
- Registration Number
- NCT02874742
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2016-07-26
- Target Recruit Count
- 110
- Registration Number
- NCT02844322
- Locations
- 🇨🇳
Shuhua Yi, Tianjin, China
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 81
- Registration Number
- NCT02811978
Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.
- Conditions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2016-06-14
- Target Recruit Count
- 100
- Registration Number
- NCT02797041
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 114
- Registration Number
- NCT02783625
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸University of Washington School of Medicine in St. Louis, Saint Louis, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.